Bain Capital Ventures Backs Forus AI Platform With $150 Million to Speed Up Patient Access to New Medicines
Healthcare startup Forus has secured $150 million in Series C funding led by Bain Capital Ventures.
The round values the company at $3 billion and brings its total capital raised to more than $300 million, just four months after its previous $160 million Series B round.
Why This Funding Matters for Everyday Patients
Forus uses artificial intelligence to automate the complex steps that come after a doctor writes a prescription.
These steps often include insurance authorization, financial assistance applications, and pharmacy and drug-supply coordination that can delay patients from starting treatment.
By giving each prescription its own AI agent, the platform aims to connect doctors, pharmacies, payers, and biopharmaceutical companies more efficiently.
This approach could help new therapies reach patients faster, especially those with serious or complex conditions where access to treatment can be critical. Forus says about one in three patients prescribed medicines for high-cost or complex conditions never receive their first dose.
The platform is designed to address a long-standing bottleneck in healthcare delivery across the United States by automating administrative work between a prescription and a patient's start of treatment.
The Rise of AI in Medicine and What Comes Next
The company was founded in 2023 and was formerly known as Tandem. It now operates across all 50 U.S. states and reaches patients in 85% of U.S. residential ZIP codes.
Its platform works with nine of the world's 15 largest biopharmaceutical companies, while adoption has expanded across medical specialties beyond its initial focus.
Future plans include expanding into more medical specialties and care settings while continuing to invest in its technology and workforce.
Investors see this as part of a broader shift toward AI-powered infrastructure that could reshape how medicines move from prescription to patient.
For ordinary people, this could mean shorter waits for innovative treatments and less friction around the paperwork, insurance approvals, and coordination involved in accessing medicines.
